Sildenafil citrate (Revatio®) solution
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000368
English
Authors' recommendations:
Sildenafil citrate (Revatio®) solution for injection is recommended within its current licensed indication as an option for use within NHS Wales for the treatment of patients with pulmonary arterial hypertension (PAH) who are currently prescribed oral sildenafil citrate and who are temporarily unable to take oral medicine, but are otherwise clinically and haemodynamically stable.
AWMSG recommends that its use be restricted to a physician experienced in the treatment of PAH.
Sildenafil citrate (Revatio®) solution for injection is not suitable for shared care within NHS Wales for the above indication.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=168033&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Hypertension, Pulmonary
- Piperazines
- Sulfones
- Purines
- Vasodilator Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.